Full Press Release Details
As chief scientific officer, Dr. Zhong leads all non-clinical scientific and research activities supporting the advancement of Ovid’s pipeline of potential first-in-class and best-in-class therapeutic candidates. Dr. Zhong oversees Ovid’s scientific strategy, the Company’s research team, and academic collaborations with the goal of accelerating research underpinning the clinical development of the Company’s pipeline assets.
Dr. Zhong joined Ovid from Generation Bio where he served as Senior Vice President and oversaw DNA Science and R&D operations from 2019 – 2022. He was previously Vice President of Biology at Wave Life Sciences from 2016 – 2019, and led the discovery of oligotherapeutics for central nervous system, hepatic/metabolic, and muscle diseases. Previously, at Vertex Pharmaceuticals, he established a research site in Shanghai before moving to Boston in 2015 to oversee external research and innovation projects. From 2008 to 2013, as part of GSK’s leadership team for neuroscience R&D, Dr. Zhong established both platform functions and a Regenerative Medicine Discovery Performance unit. He also led the GSK neuroinflammation R&D team, which delivered clinical candidates for several multiple sclerosis clinical studies.
Dr. Zhong started his career at Johnson & Johnson, developing cell assay technologies as well as leading operations and research for the start-up Cell & Molecular Technologies through its acquisition and integration by Invitrogen (now Thermo Fisher Scientific).
Dr. Zhong received his doctorate from The Rockefeller University where he discovered Stat3 and Stat4.